MIP-DILI
Primary tabs
Drug Induced Liver Injury (DILI) is a major health problem with broad implications for patients, health care professionals, the pharmaceutical industry and drug regulatory agencies. The current test systems employed by the pharmaceutical industry are poorly predictive for DILI. The Mechanism Based Integrated Systems for the Prediction of Drug Induced Liver Injury (MIP-DILI) project will address this situation by the development of innovative preclinical test systems. These will be both mechanism-based and of physiological, pharmacological and pathological relevance to DILI in humans.
MIP-DILI is an IMI/EPFIA funded consortium of 26 participants from the pharmaceutical industry, SMEs and academic institutions. The five-year project has total budget of €32.4 million and was launched on the 29th of February 2012.
